News | January 21, 2009

Ultrasound Delivery of Clot-Busting Drugs May Lessen Risk of Bleeding in Thrombolysis

January 22, 2009 - Delivering clot-busting drugs with an ultrasound-enhanced delivery system could reduce the amount of drugs needed to break up dangerous blood clots in the legs and pelvis, according to discussions surrounding a live case demonstration at the 21st annual International Symposium on Endovascular Therapy (ISET).

In a live case preformed yesterday viewed by hundreds of endovacular specialists, Constantino Peña, M.D., an interventional radiologist at Baptist Cardiac and Vascular Institute in Miami, treated a 74-year-old male with a blocked leg artery. Dr. Peña delivered the drug Tenecteplase (TNK) to the clot via ultrasound-accelerated catheter-directed thrombolysis, and the clot was completely dissolved upon examination 12 hours later.

In a discussion of the live case, Dr. Peña indicated that the amount of TNK used to dissolve the clot was half what is typically used. Lowering the amount of drug needed to dissolve clots can significantly reduce the risk of major bleeding, according to Barry Katzen, M.D., founder and medical director of Baptist Cardiac and Vascular Institute.

The International Symposium on Endovascular Therapy (ISET) is attended by more than 1,200 physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live cases to promote the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET is presented by the Baptist Cardiac and Vascular Institute, Miami.

For more information: www.ISET.org

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init